Lakefront Biotherapeutics (LKFT) Interest Coverage Ratio (2016 - 2020)
Lakefront Biotherapeutics (LKFT) reported Interest Coverage Ratio of 45.88 for Q1 2020, up 79.58% year-over-year from 25.55 in Q2 2019, and down 7.93% quarter-over-quarter from 42.51 in Q4 2019.
Lakefront Biotherapeutics (LKFT) Interest Coverage Ratio (2016 - 2020) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has 5 years of Interest Coverage Ratio data on file, last reported at 45.88 in Q1 2020.
- Interest Coverage Ratio for Q1 2020 came in at 45.88, up 79.58% year-over-year; the trailing twelve-month figure through Mar 2026 was 9.583148955696805e+17 (up 329.45% YoY), and the FY2025 annual result was 285.34, up 238.02% from the prior year.
- Interest Coverage Ratio declined to 45.88 in Q1 2020 per LKFT's latest filing, from 42.51 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 108.72 in Q3 2019 and troughed at 224.65 in Q1 2019.
- A 5-year average of 23.01 and a median of 0.65 in 2016 frame the typical range for Interest Coverage Ratio.
- On a YoY basis, Interest Coverage Ratio climbed as much as 3280.07% in 2018 and fell as far as 4592.28% in 2018.
- A 5-year view of Interest Coverage Ratio shows it stood at 0.33 in 2016, then tumbled by 201.24% to 0.98 in 2017, then surged by 3280.07% to 31.24 in 2018, then plunged by 236.08% to 42.51 in 2019, then slipped by 7.93% to 45.88 in 2020.
- Business Quant data shows LKFT's Interest Coverage Ratio at 45.88 in Q1 2020, 42.51 in Q4 2019, and 108.72 in Q3 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 3.58 |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -258.33 |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | 11.50 |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 547.67 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 11.79 |
| 10 | Lakefront Biotherapeutics | 9.64 Bn | 9.64 Bn | 1.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | -45.88 |
| Dec 31, 2019 | -42.51 |
| Sep 30, 2019 | 108.72 |
| Jun 30, 2019 | 30.14 |
| Mar 31, 2019 | -224.65 |
| Dec 31, 2018 | 31.24 |
| Sep 30, 2018 | -26.28 |
| Jun 30, 2018 | -6.08 |
| Mar 31, 2018 | -154.02 |
| Dec 31, 2017 | -0.98 |
| Sep 30, 2017 | 3.60 |
| Jun 30, 2017 | 1.42 |
| Mar 31, 2017 | 3.43 |
| Mar 31, 2016 | -0.33 |